Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
New England Journal of Medicine · 04.06.2026 · 394 (21) · 2172-2173
DOI: 10.1056/nejmc2604757 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 04.06.2026. Verfasst von Hanny Al-Samkari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Boston. Die Arbeit nennt 4 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Massachusetts General Hospital, Boston.
- Amgen, Thousand Oaks, CA.
- University of Miami Sylvester Comprehensive Cancer Center, Miami.
Zitieren
APA
Al-Samkari, H., Wang, K., & Soff, G. A. (2026). Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. New England Journal of Medicine, 394(21), 2172-2173. https://doi.org/10.1056/nejmc2604757
Vancouver
Al-Samkari H, Wang K, Soff GA. Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. New England Journal of Medicine. 2026;394(21):2172-2173. doi:10.1056/nejmc2604757
BibTeX
@article{AlSamkari2026,
author = {Al-Samkari, Hanny and Wang, Kejia and Soff, Gerald A},
title = {Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {21},
pages = {2172--2173},
doi = {10.1056/nejmc2604757}
}
EUVIMED